Q0517
Pharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription oral drug, per 60-days
- Release
- October 2026
- Effective
Official Coding Notes
Reproduced verbatim from the October 2026 HCPCS Level II files.
Note
MMA section 303(e).
Version History
How Q0517 appears in each release imported from the official files, newest first.
-
October 2026 Effective
InactivePharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription oral drug, per 60-days
-
July 2026 Effective
InactivePharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription oral drug, per 60-days
-
April 2026 Effective
InactivePharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription oral drug, per 60-days
-
January 2026 Effective
InactivePharmacy supplying fee for hiv pre-exposure prophylaxis fda approved prescription oral drug, per 60-days
Data Source
Code information on this page is derived from the October 2026 HCPCS Level II files published by CMS.
- Release
- October 2026
- Effective
- Source file
- october-2026-alpha-numeric-hcpcs-file.zip
Official HCPCS Level II source files (opens in a new tab)
MedCodeSearch is an independent reference service and is not affiliated with CMS, CDC, or the U.S. government.
Look up another code
Search ICD-10-CM, ICD-10-PCS and HCPCS Level II by code or description.